Presentation of results for fourth quarter 2012

Presentation of results for fourth quarter 2012 will take place 09:00 (Norwegian time), Friday 15 February at Felix Conference Centre, Bryggetorget 3, Aker brygge in Oslo.

The presentation will be available on webcast with the following link:

http://media01.smartcom.no/Microsite/start.aspx?eventid=7038

After the presentation the webcast will be available on demand on the webpage www.diagenic.com under ‘Investor relations’.

Contact:

Paul de Potocki, Chief Executive Officer

Telephone: +47 2324 8950

e-mail: paul.depotocki@diagenic.com

About DiaGenic ASA

DiaGenic is an innovative Norwegian diagnostic company that seeks to create value for patients, partners and investors by developing innovative and patient friendly in vitro diagnostic (IVD) products for early detection of diseases. The company’s proprietary concept implies that a disease evokes systemic responses in the blood unique for the disease, and which can be measured by using a blood sample. DiaGenic is a world leader in identifying gene expression signatures in blood and is focused on the development of IVD biomarker products in the field of Alzheimer’s disease. The company protects its technology through an extensive patent portfolio. DiaGenic is listed on the Oslo Stock Exchange. For more information please visit: www.diagenic.com

About Us

NEL ASA is a leading global supplier of hydrogen technology for industrial / energy purposes, and has made over 500 deliveries in more than 50 countries. The company's main products are hydrogen production plants based on water electrolysis, complete hydrogen stations for transport and renewable energy storage solutions. The company has its roots from the hydrogen activities of Norsk Hydro, which dates back to 1927. The company also has a number of patents related to tests for early detection and diagnosis of diseases.

Subscribe